GNH USA

Europe — EMA

Ozlam (Apremilast)

Apremilast, the active ingredient in Ozlam, is a phosphodiesterase‑4 (PDE4) inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of certain chronic inflammatory skin conditions in…

Request sourcing

1
Pack/s

What is Apremilast?

Apremilast, the active ingredient in Ozlam, is a phosphodiesterase‑4 (PDE4) inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of certain chronic inflammatory skin conditions in adult patients. GNH USA supplies Ozlam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Ozlam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

What is Apremilast used for?

Apremilast is a phosphodiesterase‑4 inhibitor used in dermatology and rheumatology to modify inflammatory pathways.

- Plaque psoriasis: reduces skin lesions and improves quality of life. - Psoriatic arthritis: alleviates joint pain and swelling. - Behçet's disease oral ulcers: promotes healing of recurrent mouth ulcers.

What are the side effects of Apremilast?

Apremilast may exhibit several     …  … …  ...  … … … …  …  

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Apremilast
Route
Oral Use
Manufacturer
Zaklady Farmaceutyczne Polpharma S.A.
Origin
EU

Related products